WO2017069567A1 - L-쓰레오닌을 생산하는 재조합 미생물 및 이를 이용하여 l-쓰레오닌을 생산하는 방법 - Google Patents
L-쓰레오닌을 생산하는 재조합 미생물 및 이를 이용하여 l-쓰레오닌을 생산하는 방법 Download PDFInfo
- Publication number
- WO2017069567A1 WO2017069567A1 PCT/KR2016/011907 KR2016011907W WO2017069567A1 WO 2017069567 A1 WO2017069567 A1 WO 2017069567A1 KR 2016011907 W KR2016011907 W KR 2016011907W WO 2017069567 A1 WO2017069567 A1 WO 2017069567A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- threonine
- seq
- microorganism
- ilva
- gene
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01182—(R)-Citramalate synthase (2.3.1.182)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y403/00—Carbon-nitrogen lyases (4.3)
- C12Y403/01—Ammonia-lyases (4.3.1)
- C12Y403/01019—Threonine ammonia-lyase (4.3.1.19)
Definitions
- the present application relates to recombinant microorganisms that produce threonine, and methods of producing L-threonine using the same.
- Threonine is an essential amino acid that is widely used in feed, food additives and animal growth promoters. It is also used as a synthetic raw material for fluids and pharmaceuticals.
- threonine degradation pathway with enhancement of threonine biosynthesis genes (ex. Ppc, aspC, thrABC) is known to improve yield (Kwang-Ho Lee). , et al., Molecular System Biology 2007). Genes on the threonine degradation pathway include tdh, tdcB, glyA, and ilvA. Among these, ilvA (Threonine Deaminase) is known as the major threonine degradation gene.
- Corynebacterium spp. Or Escherichia spp. Strains produce 2-ketobutyrate and biosynthesize isoleucine through the ilvA gene, which is a threonine degradation pathway.
- Methanococcus Microorganisms such as jannaschii are known to be able to synthesize 2-ketobutyl acid and isoleucine based on acetyl-CoA and pyruvate via citramalate synthase (cimA) (Atsumi, Liao JC, Appl Environ Microbiol., 2008).
- the present inventors have made intensive efforts to develop a method for effectively producing threonine, and as a result, the activity of the threonine deaminase (IlvA) enzyme in the threonine producing strain is reduced, and the citramalate synthetase (cimA) gene can improve the yield of threonine production and overcome the existing problems of delayed culture due to acetate accumulation (Xie X, et al., J Ind Microbiol Biotechnol. 2014). It confirmed and completed this application.
- One object of the present application is to provide a recombinant microorganism that produces threonine with high efficiency.
- Another object of the present application is to provide a method for producing threonine using the microorganism.
- the recombinant microorganism producing threonine of the present application reduces or inactivates the activity of threonine deaminase (ilvA) and introduces the activity of citramalate synthase (cimA). As a result, the accumulation of acetate in the microorganisms is reduced or improved, and the threonine production is excellent. Accordingly, the industrial scale may be widely used for the efficient and economic production of threonine.
- Fig. 2 is a schematic diagram showing a gene map of the introduction plasmid pMu-R6K plasmid used in the mini-Mu gene insertion method used for introduction of a threonine biosynthesis gene.
- one aspect of the present application is to reduce or inactivate the activity of threonine deaminase (IlvA), having the activity of citramalate synthase (citramalate synthase), Provided are recombinant microorganisms that produce threonine.
- IlvA threonine deaminase
- citramalate synthase citramalate synthase
- threonine refers to an amino acid having the formula HO 2 CCH (NH 2 ) CH (OH) CH 3 as one of the essential amino acids which are not produced in the body as hydroxy- ⁇ -amino acid.
- threonine may be the optical isomer L type or D type, but is not limited thereto.
- producing threonine in the present application means the ability to produce and accumulate threonine in or on the microorganism when the microorganism is cultured in the medium.
- Such threonine producing ability may be a property retained by a wild type strain or a property conferred or enhanced by strain improvement.
- threonine deaminase (EC4.3.1.19) is also referred to as threonine ammonia-lyase or threonine dehydratase and the like. It is an enzyme that catalyzes the conversion of leonin into ⁇ -ketobutyrate and ammonia. Since the ⁇ -ketobutyrate thus produced is used as a precursor of isoleucine, the biosynthesis of isoleucine is not normal when the threonine deaminase is deficient, which may inhibit the growth of microorganisms.
- threonine deaminase enzyme and “gene encoding the same” may include any protein having such a threonine deaminase activity and any gene encoding the same without limitation.
- the threonine deaminase can be easily obtained from a known database such as the American Biotechnology Information Center (NCBI) or the Japanese DNA Data Bank (DDBJ), for example, the amino acid sequence of SEQ ID NO. It may be.
- NCBI American Biotechnology Information Center
- DDBJ Japanese DNA Data Bank
- amino acid sequence of SEQ ID NO: 7 is at least 70%, specifically at least 80%, more specifically at least 90%, even more specifically at least 95%, even more specifically at least 98%, most specifically 99 Any protein having substantially threonine deaminase activity as an amino acid sequence showing at least% homology may be included in the scope of the present application without limitation.
- sequence having homology with the sequence is an amino acid sequence having a biological activity substantially the same as or corresponding to that of the protein of SEQ ID NO: 7, some sequences have an amino acid sequence deleted, modified, substituted or added. Obviously included in the scope of the application.
- the gene encoding the threonine deaminase may have a base sequence encoding the amino acid sequence represented by SEQ ID NO: 7.
- the polynucleotide may be variously modified in the coding region due to degeneracy of the codon or in consideration of the codon preferred in the organism to express the protein, without changing the amino acid sequence of the protein.
- the polynucleotide sequence may have, for example, a polynucleotide sequence of SEQ ID NO: 30, and may have a nucleotide sequence having an homology of 80%, specifically 90% or more, more specifically 99% or more. However, it is not limited thereto.
- homology means the degree of coincidence with a given amino acid sequence or base sequence and may be expressed in percentage.
- homologous sequences thereof having the same or similar activity as a given amino acid sequence or base sequence are designated as "% homology".
- % homology For example, using standard software that calculates parameters such as score, identity and similarity, in particular BLAST 2.0, or by hybridization experiments used under defined stringent conditions The appropriate hybridization conditions to be defined are within the scope of the art (see, eg, Sambrook et al., Molecular Cloning: A Laboratory Manual 1989) and can be determined by methods well known to those skilled in the art.
- reduced activity of an enzyme means that the activity of the enzyme is reduced compared to the intrinsic activity of the wild type or pre-mutation state.
- activation in the present application means that when the expression of the gene encoding the enzyme is reduced to a low level or no expression at all compared to the wild strain, and even if the expression is not active or reduced. Reduction or inactivation of the enzyme can be accomplished by any method known in the art.
- deletion of part or all of the polynucleotide encoding the enzyme modification of the expression control sequence to reduce the expression of the polynucleotide, modification of the polynucleotide sequence on the chromosome to attenuate the activity of the protein, or a combination thereof It may be carried out in the method selected from, but is not particularly limited thereto.
- the method for deleting a part or all of the polynucleotide encoding the protein is performed by replacing a polynucleotide encoding an intrinsic target protein in a chromosome with a polynucleotide or a marker gene in which some nucleic acid sequences are deleted through a bacterial chromosome insertion vector. Can be performed.
- a method of modifying an expression control sequence so that expression of the polynucleotide is reduced or deleted is not particularly limited, and the nucleic acid sequence may be deleted, inserted, non-conserved, or conserved to further weaken the activity of the expression control sequence. It can be carried out by inducing a mutation on an expression control sequence by substitution or a combination thereof, or by replacing with a nucleic acid sequence having weaker activity.
- the expression control sequence may include a promoter, an operator sequence, a sequence encoding a ribosomal binding site, and a sequence that controls the termination of transcription and translation, but is not limited thereto.
- a method of modifying a polynucleotide sequence on a chromosome is carried out by inducing a mutation in the sequence by deletion, insertion, non-conservative or conservative substitution, or a combination thereof to further weaken the activity of the protein, or weaker. It can be carried out by replacing with a polynucleotide sequence modified to have activity, but is not limited thereto.
- the term "recombinant vector” refers to a DNA preparation containing a nucleotide sequence of a polynucleotide encoding said target protein operably linked to a suitable regulatory sequence to enable expression of the target protein in a suitable host.
- the regulatory sequence may comprise a promoter capable of initiating transcription, any operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosomal binding site, and a sequence regulating termination of transcription and translation.
- the recombinant vector can be transformed into a suitable host cell and then replicated or functioned independently of the host genome and integrated into the genome itself.
- the recombinant vector used in the present application is not particularly limited as long as it is replicable in a host cell, and may be produced using any vector known in the art.
- Examples of commonly used vectors include natural or recombinant plasmids, cosmids, viruses and bacteriophages.
- pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, Charon21A, etc. can be used as a phage vector or cosmid vector, and pBR-based, pUC-based, pBluescriptII-based, etc.
- pGEM-based, pTZ-based, pCL-based and pET-based and the like can be used.
- the vector usable in the present application is not particularly limited and known expression vectors can be used. Specifically, pECCG117, pDZ, pACYC177, pACYC184, pCL, pUC19, pBR322, pMW118, pCC1BAC vector and the like can be used.
- a polynucleotide encoding a target protein in a chromosome may be introduced through a chromosome insertion vector in a host cell.
- Introduction of the polynucleotide into the chromosome may be by any method known in the art, for example, homologous recombination, but is not limited thereto.
- transformation in the present application means introducing a recombinant vector comprising a polynucleotide encoding a target protein into a host cell so that the protein encoded by the polynucleotide can be expressed in the host cell.
- the transformed polynucleotide it may include all of them, whether inserted into the chromosome of the host cell or located outside the chromosome.
- operably linked means that the gene sequence is functionally linked with a promoter sequence for initiating and mediating the transcription of a polynucleotide encoding a target protein of the present application.
- citramalate synthase (EC2.3.1.182) is an enzyme that catalyzes the process of converting acetyl-CoA and pyruvate to citramalate and coenzyme A. This enzyme is called Methanococcus jannaschii ) (Howell et al., J Bacteriol. 181: 331-333, 1999), Leptospira interogans (Xu et al., J Bacteriol.
- Geobacter Sulfurdu It has been found in archaea such as Geobacter sulfurreducens and participates in the threonine-independent pathway of isoleucine biosynthesis (Risso et al., J Bacteriol. 190: 2266-2274, 2008).
- the enzyme has high specificity for pyruvate as a substrate and is typically inhibited by isoleucine.
- citramalate synthase enzyme and “gene encoding it” include without limitation any protein having such citramalate synthase activity and any gene encoding the same.
- sequence of the enzyme can be easily obtained from a known database such as the American Biotechnology Information Center (NCBI) or the Japanese DNA Data Bank (DDBJ).
- it may be citramalate synthase derived from Metanococcus yanashi, and may be composed of an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.
- the gene encoding the citramalate synthase may have a base sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3.
- the polynucleotide sequence for example, may have a nucleotide sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, the homology thereof is 80% or more, specifically 90% As described above, more specifically, it may have a nucleotide sequence of 99% or more, but is not limited thereto.
- a protein having substantially citramalate synthase activity as an amino acid sequence showing at least 98% and most specifically at least 99% may be included in the scope of the present application without limitation.
- sequence has homology with the sequence and the amino acid sequence having the same or corresponding biological activity as the protein of the amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, some sequences It is obvious that cases having amino acid sequences deleted, modified, substituted or added are also included in the scope of the present application.
- the term “recombinant microorganism” may include without limitation genetically engineered mutant microorganisms, and if genetically engineered is possible, genus Escherichia , Corynebacterium , Brevibacterium It may be, but not limited to, genus Serratia , genus Providencia .
- the recombinant microorganism of the present application may be a Corynebacterium microorganism or Escherichia microorganism, in particular the Corynebacterium microorganism may be Corynebacterium glutamicum ,
- the microorganism of the genus Escherichia may be Escherichia coli .
- the recombinant microorganism may be naturally a strain having a threonine-producing ability as a parent strain, or may be a strain having a mutation introduced therein to enhance the threonine-producing ability.
- Mutations that enhance the threonine production capacity may be, for example, to enhance genes associated with threonine biosynthesis or to attenuate genes associated with threonine degradation pathways.
- the gene associated with the threonine biosynthesis is the pntAB gene encoding pyridine nucleotide transhydrogenase, the asd encoding the aspartate- ⁇ -semialdehyde dehydrogenase.
- Gene an aspC gene encoding aspartate aminotransferase, a gdhA gene encoding glutamate dehydrogenase, phosphoenol pyruvate carboxylase It may be one or more genes selected from the group consisting of the ppc gene, the aspA gene encoding aspartase, the threonine operon (thrO), and the gene associated with the threonine degradation pathway is threonine dehydrogena.
- Tdh gene kata, encoding threonine dehydrogenase It may be a metallic threonine di Hydra hydratase one or more genes selected from the group consisting of the genes tdcB, etc. encoding the (catabolic threonine hydratase).
- Another aspect of the present application provides a method of producing threonine, comprising culturing the recombinant microorganism of the present application in a medium, and recovering threonine from the microorganism or the medium.
- culturing a recombinant microorganism producing threonine in which the activity of the threonine deaminase enzyme is reduced or inactivated and the activity of the citramalate synthase enzyme is introduced, and the microorganism or It provides a method for producing threonine comprising recovering threonine from the medium.
- Recombinant microorganisms producing the threonine deaminase, citramalate synthase, and threonine in the present application are as described above.
- the term "culture” refers to the growth of microorganisms under appropriately artificially controlled environmental conditions.
- the step of culturing microorganisms for example, Corynebacterium microorganisms or Escherichia microorganisms may use any culture conditions and culture methods known in the art.
- the step of culturing the microorganism according to the present application for example, Corynebacterium microorganism or Escherichia microorganism is not particularly limited, but known batch culture method, continuous culture Method, fed-batch culture method and the like.
- the medium used for the culture must meet the requirements of the particular strain in an appropriate manner and those skilled in the art can appropriately use it according to the known contents.
- Culture media for Corynebacterial strains or Escherichia spp. Strains are known (e.g., Manual of Methods for General Bacteriology. American Society for Bacteriology.Washington D.C., USA, 1981).
- the culture conditions are not particularly limited thereto, but using a basic compound (for example, sodium hydroxide, potassium hydroxide or ammonia) or an acidic compound (for example, phosphoric acid or sulfuric acid), an appropriate pH (for example, pH 5 to 9, preferably PH 6 to 8, most preferably pH 6.8).
- a basic compound for example, sodium hydroxide, potassium hydroxide or ammonia
- an acidic compound for example, phosphoric acid or sulfuric acid
- an appropriate pH for example, pH 5 to 9, preferably PH 6 to 8, most preferably pH 6.8.
- antifoaming agents such as fatty acid polyglycol esters can be used to inhibit bubble generation.
- Oxygen or an oxygen-containing gas mixture may be introduced into the culture to maintain aerobic conditions, and the temperature of the culture is usually 20 ° C. to 45 ° C., preferably 25 ° C. to 40 ° C. Incubation is continued until maximum production of threonine is obtained. For this purpose it is usually achieved in 10 to 160 hours. Threonine may be excreted in the culture medium or contained in cells.
- the culture medium used may include sugars and carbohydrates (e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose), fats and fats (e.g. soybean oil, sunflower seeds) as carbon sources.
- sugars and carbohydrates e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose
- fats and fats e.g. soybean oil, sunflower seeds
- fatty acids e.g. palmitic acid, stearic acid and linoleic acid
- alcohols e.g. glycerol and ethanol
- organic acids e.g. acetic acid
- Nitrogen sources include nitrogen-containing organic compounds such as peptone, yeast extract, gravy, malt extract, corn steep liquor, soybean meal and urea, or inorganic compounds such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and Ammonium nitrate) and the like can be used individually or in combination, but is not limited thereto.
- organic compounds such as peptone, yeast extract, gravy, malt extract, corn steep liquor, soybean meal and urea
- inorganic compounds such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and Ammonium nitrate
- potassium dihydrogen phosphate dipotassium hydrogen phosphate
- sodium-containing salts may be used individually or in combination, but is not limited thereto.
- metal salts such as magnesium sulfate or iron sulfate
- essential growth-promoting substances such as, but not limited to, amino acids and vitamins.
- suitable precursors to the culture medium may be used.
- the raw materials described above may be added batchwise or continuously in a suitable manner to the culture in the culture process, but is not limited thereto.
- the step of recovering threonine from the microorganism or the medium may be performed by a suitable method known in the art according to a culture method, for example, batch, continuous or fed-batch culture method.
- a suitable method known in the art according to a culture method, for example, batch, continuous or fed-batch culture method.
- the known threonine recovery method is not particularly limited, but centrifugation, filtration, extraction, spraying, drying, thickening, precipitation, crystallization, electrophoresis, fractional dissolution (eg ammonium sulfate precipitation), chromatography (Eg, HPLC, ion exchange, affinity, hydrophobicity and size exclusion) may be used, but is not limited thereto.
- the activity of the threonine deaminase (IlvA) is reduced or inactivated and provides for the production of threonine of recombinant microorganisms having the activity of citramalate synthase.
- a recombinant microorganism producing threonine in which the activity of threonine deaminase (IlvA) is reduced or inactivated and has the activity of a citramalate synthase. Is as described above.
- the recombinant microorganism producing threonine of the present application reduces or inactivates the activity of threonine deaminase (ilvA), and the citramalate synthase (cimA) By introducing the activity of), growth capacity is maintained or improved as the amount of acetate accumulation in the microorganism is reduced, and has excellent threonine production capacity.
- threonine deaminase threonine deaminase
- cimA citramalate synthase
- Example 1 Production of wild type E. coli-based threonine producer
- the mini-Mu transposon based genome insertion method (Akhverdyan VZ, Gak ER et al., Appl Microbiol Biotechnol. 2011) was used to produce threonine from wild type E. coli W3110 (Accession Number ATCC9637).
- a helper plasmid (p. 1) named pCJ-MuAB and an integrative plasmid (p. 2) named pMu-R6K were prepared.
- helper plasmid is expressed by using arabinose-inducible ParaB promoter to express transposition factors, MuA and MuB, and to easily remove plasmids including temperature sensitive replicon It became.
- pMu-R6K the plasmid for introduction, has a cat gene containing mu-attL / R, a mini-Mu unit, and loxP66 and loxP71 (Oleg Tolmachov, et al., Biotechnol. 2006) on both sides. And a suicidal vector that does not proliferate in normal E. coli without R6K replicon (Xiao-Xing Wei, Zhen-Yu Shi. Et al., Appl Microbiol Biotechnol. 2010). ).
- Three introduction plasmids were prepared to enhance the expression of threonine biosynthetic gene using the plasmid prepared in Example 1-1.
- An introductory pMu-R6K plasmid prepared in Example 1-1 was purified by DNA after SmaI restriction enzyme treatment to prepare a cleaved linear cloning vector.
- the pntAB gene was amplified by PCR of SEQ ID NO: 8 and SEQ ID NO: 9 with W3110 genomic DNA as a template.
- the denaturation step using SolGent TM Pfu-X DNA Polymerase is 30 seconds at 94 ° C.
- the annealing step is 30 seconds at 55 ° C.
- the extension step is 72 ° C. Run for 3 minutes, and this was done 30 times.
- W3110 genomic DNA was used as a template to sequence SEQ ID NO: 10 and SEQ ID NO: 11 with a primer to amplify the asd gene in the same manner as described above, and SEQ ID NO: 12 and SEQ ID NO: 13 with a primer PCR aspC gene as described above Amplified by.
- Threonine operon was amplified by PCR of SEQ ID NO: 14 and SEQ ID NO: 15 from KCCM10541 (Korean Patent No. 10-0576342) genomic DNA.
- PMu-R6K_pntAB asd aspC-thrO plasmid was prepared from each of the four types of DNA and vector DNA prepared above (Daniel G Gibson, et al., Nature Methods 2009).
- the Gibson assembly method is first prepared 5X ISO buffer with the composition of Table 1, and then 5X ISO buffer and T5 exonuclease (Epicentre), phusion polymerase (New England Biolabs), Taq ligase (New England Biolabs) 15 ⁇ l of Gibson assembly mater mix mixed with three enzymes and 5 ⁇ l of DNA to be cloned are reacted at 50 ° C. for 1 hour. Then, an electric shock (2500 V) was applied to the TransforMaxTM EC100DTM pir-116 Electrocompetent E. coli (epicentre, USA) competent cells.
- Gibson assembly master mix composition ingredient content 5X ISO Buffer 320 uL 10 U / uL T5 exonuclease 0.64 uL 2 U / uL Phusion polymerase 20 uL 40 U / uL Taq ligase 160 uL total dH 2 O up to 1.2 mL
- the pMu-R6K plasmid for introduction prepared in Example 1-1 was digested with pMu-R6K plasmid after SmaI restriction enzyme treatment in the same manner as in 1-2-1 to prepare a cleaved linear cloning vector.
- the gdhA gene was amplified by PCR using SEQ ID NO: 18 and SEQ ID NO: 19 with primers
- the aspC gene was amplified by PCR using SEQ ID NO: 20 and SEQ ID NO: 21 with primers.
- thrO threonine operon
- thrO amplified thrO (threonine operon) by PCR with primers SEQ ID NO: 14 and SEQ ID NO: 15 from KCCM10541 genomic DNA.
- PMu-R6K_gdhA aspC thrO plasmid was prepared from each of the three types of DNA and vector DNA prepared above by Gibson assembly.
- the pMu-R6K plasmid for introduction prepared in Example 1-1 was digested with pMu-R6K plasmid after SmaI restriction enzyme treatment in the same manner as in 1-2-1 to prepare a cleaved linear cloning vector.
- the primers were amplified from the W3110 genomic DNA by PCR with SEQ ID NO: 22 and SEQ ID NO: 23, and the aspA gene was amplified by PCR with SEQ ID NO: 24 and SEQ ID NO: 25 with primers.
- the thrO (threonine operon) was amplified by PCR with SEQ ID NO: 26 and SEQ ID NO: 27 from KCCM10541 genomic DNA.
- PMu-R6K_ppc aspA thrO plasmid was prepared from each of the three types of DNA and vector DNA prepared above by Gibson assembly.
- W3110 wild-type E. coli transformed with pCJ-MuAB prepared in Example 1-1 was incubated to OD 600 0.6 at 30 ° C using LB medium containing 100 ug / L Ampicillin and 5 mM arabinose. Competent cells were prepared by centrifugation once with sterile distilled water and twice with 10% glycerol (Sambrook and Russell 2001). The prepared plasmid, pMu-R6K_pntAB asd aspC-thrO, was added to the prepared competent cells, followed by electroporation, and incubated at 37 ° C for 1 hour after addition of 1 mL SOC medium.
- Chloramphenicol Chloramphenicol
- LB plate medium containing chloramphenicol resistant bacteria colony was carried out by colony PCR with SEQ ID NO: 10 and SEQ ID NO: 15 to confirm that the pntAB asd aspC thrO gene was introduced on the genome.
- chloramphenicol resistant markers catalog were removed by smearing on 0.1 L IPTG-added LB plates (Beatri'z Palmeros et al., 2000, Gene).
- PMu-R6K_gdhA aspC thrO was sequentially introduced by the mini-Mu integration method as described above, followed by colony PCR with SEQ ID NO: 18 and SEQ ID NO: 15 to confirm the introduction. After introduction of pMu-ppc aspA thrO, SEQ ID NO: 22 and SEQ ID NO: 27 Colony PCR was used to confirm the introduction.
- the wild-type Escherichia coli (W3110) -based threonine producing strain thus produced was named CJT1.
- the FRT-one-step-PCR deletion method was used (Kirill A, et al., 2000, PNAS).
- Deletion cassettes were prepared by PCR using the primers of SEQ ID NO: 28 and SEQ ID NO: 29 using the pKD3 vector as a template. Denaturation step using SolGent TM Pfu-X DNA Polymerase (solgent, Korea) at 94 ° C for 30 seconds, annealing step at 55 ° C for 30 seconds and extension step at 72 ° C for 3 minutes was carried out for 30 times.
- IlvA gene deletion was confirmed by colony PCR of the selected strains with primers of SEQ ID NO: 28 and SEQ ID NO: 29 and confirming that the gene size was observed at 1.2 kb on a 1.0% agarose gel.
- the identified strain was again transformed with pCP20 vector (Kirill A, et al., 2000, PNAS) to 1.0% via colony PCR under the same conditions again in colony obtained by plating in 100 ug / L ampicilin LB plate medium.
- the final ilvA gene deficient strain with the gene size reduced to 150 bp on an agarose gel was prepared and confirmed that the chloramphenicol marker was removed.
- a strain lacking ilvA in KCCM10541 was named KCCM10541-ilvA and a strain lacking ilvA in CJT1 was named CJT1-ilvA.
- Methanococcus with CJ1 promoter (Korean Patent No. 10-0620092) Codon-optimization was performed based on jannaschii derived cimA gene to prepare Pcj1_cimA, Pcj1_cimA 2.0, Pcj1_cimA 3.7 (Atsumi, Liao JC, Appl Environ Microbiol. 2008) DNA.
- KCCM10541-ilvA and CJT1-ilvA strains were transformed into three types of plasmid and control plasmid pCC1BAC by an electric shock (2500V) method to finally produce a strain to be used in the experiment.
- strains transformed with pCC1BAC in two strains, KCCM10541 and CJT1 were prepared as described above.
- the cimA gene encodes a wild type citramalate synthase, and cimA 2.0 and cimA 3.7 are mutant citramalates with increased specific activity and reduced feedback-inhibition by isoleucine. Encode the synthetase (Atsumi, Liao JC, Appl Environ Microbiol. 2008).
- the amino acid sequences for cimA 2.0 and cimA 3.7 are SEQ ID NOs: 2 and 3, respectively, and the nucleotide sequences correspond to SEQ ID NOs: 5 and 6.
- KCCM10541 or KCCM10541-ilvA KCCM10541 pCC1BAC Based on the KCCM10541 or KCCM10541-ilvA KCCM10541 pCC1BAC, KCCM10541-ilvA pCC1BAC: Pcj1_cimA, KCCM10541-ilvA pCC1BAC: Based on ilvA, recombinant microorganisms of CJT1 pCC1BAC, CJT1-ilvA pCC1BAC, CJT1-ilvA pCC1BAC: Pcj1_cimA, CJT1-ilvA pCC1BAC: Pcj1_cimA 2.0, CJT1-ilvA pCC1BAC: Pcj1_cimA 3.7 were prepared.
- Example 4 Threonine via Flask Evaluation of ilvA Deficient and cimA Expressing Strains Productivity Check
- Flask evaluation was performed to compare the threonine production of the strains prepared in Example 3.
- the flask test streaked each strain into 25 ug / L Chloramphenicol LB plates and incubated for 16 hours in a 33 ° C. incubator, then inoculated a single colony into 2 mL of LB medium and then 200 rpm. Incubated for 12 hours in a / 33 °C incubator.
- 25 mL of the threonine production flask medium of Table 3 was added to a 250 mL flask, and 500 ⁇ L of the culture medium previously cultured was added thereto.
- the flask was incubated for 48 hours at 200 rpm / 33 °C incubator, and then compared to the amount of threonine obtained in each strain using HPLC, the results are shown in Table 4 below.
- Threonine Production Flask Medium Composition Composition Concentration (per liter) glucose 70 g Ammonium sulfate 25 g KH 2 PO 4 1 g MgSO 4 7 H 2 O 0.5 g FeSO 4 7H 2 O 5 mg MnSO 4 8H 2 O 5 mg ZnSO 4 5 mg Calcium carbonate 30 g Yeast extract 2 g Methionine 0.3 g pH 6.8
- Threonine Production in Production Strains by Flask Culture Strain OD Sugar Consumption (g / L) Threonine Production (g / L) Acetate production amount (g / L) KCCM10541 pCC1BAC 21.6 70 34.7 0.35 KCCM10541-ilvApCC1BAC 5.5 12.0 6.6 0.11 KCCM10541-ilvApCC1BAC: Pcj1_cimA 18.5 70 37.5 0.15 KCCM10541-ilvApCC1BAC: Pcj1_cimA 2.0 22.5 70 38.3 0.10 KCCM10541-ilvApCC1BAC: Pcj1_cimA 3.7 23.2 70 37.8 0.08 CJT1pCC1BAC 35.2 70 11.4 2.15 CJT1-ilvApCC1BAC 6.4 13.6 3.0 1.24 CJT1-ilvApCC1BAC: Pcj1_cimA 30.6 70 14.3 1.42 CJT1-ilvApCC1
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
성분 | 함유량 |
1M Tris-HCl pH 7.5 | 3 mL |
2M MgCl2 | 150 uL |
100nM dNTP mix | 240 uL |
1M DTT | 300 uL |
PEG-8000 | 1.5 g |
100 mM NAD | 300 uL |
총합 | dH2O up to 6 mL |
성분 | 함유량 |
5X ISO 버퍼 | 320 uL |
10 U/uL T5 exonuclease | 0.64 uL |
2 U/uL Phusion polymerase | 20 uL |
40 U/uL Taq ligase | 160 uL |
총합 | dH2O up to 1.2 mL |
조성물 | 농도(리터당) |
포도당 | 70 g |
Ammonium Sulfate | 25 g |
KH2PO4 | 1 g |
MgSO4·7H2O | 0.5 g |
FeSO4·7H2O | 5 mg |
MnSO4·8H2O | 5 mg |
ZnSO4 | 5 mg |
탄산칼슘 | 30 g |
효모 엑기스 | 2 g |
메치오닌 | 0.3 g |
pH | 6.8 |
균주 | OD | 당 소모량(g/L) | 쓰레오닌 생산량(g/L) | Acetate 생성량(g/L) |
KCCM10541 pCC1BAC | 21.6 | 70 | 34.7 | 0.35 |
KCCM10541-ilvApCC1BAC | 5.5 | 12.0 | 6.6 | 0.11 |
KCCM10541-ilvApCC1BAC:Pcj1_cimA | 18.5 | 70 | 37.5 | 0.15 |
KCCM10541-ilvApCC1BAC:Pcj1_cimA 2.0 | 22.5 | 70 | 38.3 | 0.10 |
KCCM10541-ilvApCC1BAC:Pcj1_cimA 3.7 | 23.2 | 70 | 37.8 | 0.08 |
CJT1pCC1BAC | 35.2 | 70 | 11.4 | 2.15 |
CJT1-ilvApCC1BAC | 6.4 | 13.6 | 3.0 | 1.24 |
CJT1-ilvApCC1BAC:Pcj1_cimA | 30.6 | 70 | 14.3 | 1.42 |
CJT1-ilvApCC1BAC:Pcj1_cimA 2.0 | 36.0 | 70 | 14.7 | 1.32 |
CJT1-ilvApCC1BAC:Pcj1_cimA 3.7 | 37.0 | 70 | 14.5 | 1.34 |
Claims (7)
- 쓰레오닌 디아미나제 효소(threonine deaminase, IlvA)의 활성이 감소 또는 불활성화되고, 시트라말레이트 신타아제 효소(citramalate synthase)의 활성을 가지는, 쓰레오닌을 생산하는 재조합 미생물.
- 제1항에 있어서, 상기 쓰레오닌 디아미나제는 서열번호 7의 아미노산 서열로 구성되는, 쓰레오닌을 생산하는 재조합 미생물.
- 제1항에 있어서, 상기 시트라말레이트 신타아제는 메타노코커스 야나시(Methanococcus jannaschii) 유래의 시트라말레이트 신타아제인, 쓰레오닌을 생산하는 재조합 미생물.
- 제1항에 있어서, 상기 시트라말레이트 신타아제는 서열번호 1, 서열번호 2 및 서열번호 3으로 구성된 군으로부터 선택되는 아미노산 서열로 구성되는, 쓰레오닌을 생산하는 재조합 미생물.
- 제1항에 있어서, 상기 재조합 미생물은 코리네박테리움 속 미생물 또는 에스케리키아 속 미생물인, 쓰레오닌을 생산하는 재조합 미생물.
- 제5항에 있어서, 상기 코리네박테리움 속 미생물은 코리네박테리움 글루타미쿰(Corynebacterium glutamicum)이고, 상기 에스케리키아 속 미생물은 대장균(Escherichia coli)인, 쓰레오닌을 생산하는 재조합 미생물.
- 제1항 내지 제6항 중 어느 한 항의 재조합 미생물을 배지에서 배양하는 단계, 및 상기 미생물 또는 배지로부터 쓰레오닌을 회수하는 단계를 포함하는, 쓰레오닌을 생산하는 방법.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2018117175A RU2018117175A (ru) | 2015-10-23 | 2016-10-21 | Рекомбинантный микроорганизм для получения L-треонина и способ получения L-треонина с использованием указанного микроорганизма |
EP16857824.3A EP3366776A4 (en) | 2015-10-23 | 2016-10-21 | RECOMBINANT MICROORGANISM FOR THE PRODUCTION OF L-THREONIN AND PROCESS FOR PRODUCING L-THREONIN USING THE SAME |
BR112018008045A BR112018008045A2 (pt) | 2015-10-23 | 2016-10-21 | micro-organismo recombinante que produz l-treonina e um método para produzir l-treonina com o uso do mesmo |
CN201680061611.4A CN108473992A (zh) | 2015-10-23 | 2016-10-21 | 生产l-苏氨酸的重组微生物和使用其生产l-苏氨酸的方法 |
JP2018516546A JP2018529354A (ja) | 2015-10-23 | 2016-10-21 | L−トレオニンを生産する組み換え微生物及びそれを用いてl−トレオニンを生産する方法 |
US15/769,920 US20200248218A1 (en) | 2015-10-23 | 2016-10-21 | A recombinant microorganism producing l-threonine and a method for producing l-threonine using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0148004 | 2015-10-23 | ||
KR1020150148004A KR101804017B1 (ko) | 2015-10-23 | 2015-10-23 | L-쓰레오닌을 생산하는 재조합 미생물 및 이를 이용하여 l-쓰레오닌을 생산하는 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017069567A1 true WO2017069567A1 (ko) | 2017-04-27 |
Family
ID=58557371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/011907 WO2017069567A1 (ko) | 2015-10-23 | 2016-10-21 | L-쓰레오닌을 생산하는 재조합 미생물 및 이를 이용하여 l-쓰레오닌을 생산하는 방법 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20200248218A1 (ko) |
EP (1) | EP3366776A4 (ko) |
JP (1) | JP2018529354A (ko) |
KR (1) | KR101804017B1 (ko) |
CN (1) | CN108473992A (ko) |
BR (1) | BR112018008045A2 (ko) |
RU (1) | RU2018117175A (ko) |
WO (1) | WO2017069567A1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109266578B (zh) * | 2018-09-25 | 2020-06-23 | 江苏澳创生物科技有限公司 | 大肠埃希氏菌ACThr1032及其在发酵生产L-苏氨酸中的应用 |
KR102126951B1 (ko) * | 2019-09-26 | 2020-06-26 | 씨제이제일제당 주식회사 | 디하이드로디피콜린산 리덕타제 변이형 폴리펩티드 및 이를 이용한 l-쓰레오닌 생산방법 |
CN116622597A (zh) * | 2022-02-10 | 2023-08-22 | 廊坊梅花生物技术开发有限公司 | 高产苏氨酸工程菌的构建方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080082880A (ko) * | 2007-03-09 | 2008-09-12 | 한국과학기술원 | 부위특이적 변이에 의해 제조된 고수율의 l-쓰레오닌생산균주 및 이를 이용한 l-쓰레오닌의 제조방법 |
KR100966324B1 (ko) * | 2008-01-08 | 2010-06-28 | 씨제이제일제당 (주) | 향상된 l-쓰레오닌 생산능을 갖는 대장균 및 이를 이용한l-쓰레오닌의 생산 방법 |
KR20140044470A (ko) * | 2012-10-05 | 2014-04-15 | 상지대학교산학협력단 | GntK 활성 조절을 통해 L-쓰레오닌 생산능이 향상된 코리네박테리움 속 미생물 및 이를 이용한 L-쓰레오닌 생산 방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100451299B1 (ko) * | 2002-03-21 | 2004-10-06 | 씨제이 주식회사 | L―쓰레오닌의 제조방법 |
CN1597974A (zh) * | 2003-09-17 | 2005-03-23 | 广东肇庆星湖生物科技股份有限公司 | 大肠杆菌生产l-苏氨酸 |
DE102004013503A1 (de) * | 2004-03-18 | 2005-10-06 | Degussa Ag | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung coryneformer Bakterien |
CN101580813A (zh) * | 2008-05-12 | 2009-11-18 | 长春大成实业集团有限公司 | 应用发酵生产l-苏氨酸的方法 |
KR101841261B1 (ko) * | 2011-06-29 | 2018-05-08 | 한국과학기술원 | 개선된 프로판올 생성능을 가지는 변이 미생물 및 이를 이용한 프로판올의 제조방법 |
-
2015
- 2015-10-23 KR KR1020150148004A patent/KR101804017B1/ko active IP Right Grant
-
2016
- 2016-10-21 WO PCT/KR2016/011907 patent/WO2017069567A1/ko active Application Filing
- 2016-10-21 RU RU2018117175A patent/RU2018117175A/ru not_active Application Discontinuation
- 2016-10-21 EP EP16857824.3A patent/EP3366776A4/en not_active Withdrawn
- 2016-10-21 JP JP2018516546A patent/JP2018529354A/ja active Pending
- 2016-10-21 CN CN201680061611.4A patent/CN108473992A/zh active Pending
- 2016-10-21 BR BR112018008045A patent/BR112018008045A2/pt not_active Application Discontinuation
- 2016-10-21 US US15/769,920 patent/US20200248218A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080082880A (ko) * | 2007-03-09 | 2008-09-12 | 한국과학기술원 | 부위특이적 변이에 의해 제조된 고수율의 l-쓰레오닌생산균주 및 이를 이용한 l-쓰레오닌의 제조방법 |
KR100966324B1 (ko) * | 2008-01-08 | 2010-06-28 | 씨제이제일제당 (주) | 향상된 l-쓰레오닌 생산능을 갖는 대장균 및 이를 이용한l-쓰레오닌의 생산 방법 |
KR20140044470A (ko) * | 2012-10-05 | 2014-04-15 | 상지대학교산학협력단 | GntK 활성 조절을 통해 L-쓰레오닌 생산능이 향상된 코리네박테리움 속 미생물 및 이를 이용한 L-쓰레오닌 생산 방법 |
Non-Patent Citations (4)
Title |
---|
ATSUMI ET AL.: "Directed Evolution ofMethanococcus Jannaschii Citramalate Synthase for Biosynthesis of 1-propanol and 1-butanol by Escherichia Coli", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 74, no. 24, December 2008 (2008-12-01), pages 7802 - 7808, XP002671575 * |
DATABASE NCBI [O] 28 February 1994 (1994-02-28), XP055377834, Database accession no. AAA24024.1 * |
DATABASE NCBI. [O] 22 September 2015 (2015-09-22), XP055377839, Database accession no. WP_010870909.1 * |
See also references of EP3366776A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP3366776A1 (en) | 2018-08-29 |
BR112018008045A2 (pt) | 2018-11-13 |
RU2018117175A (ru) | 2019-11-26 |
KR101804017B1 (ko) | 2017-12-04 |
US20200248218A1 (en) | 2020-08-06 |
KR20170047642A (ko) | 2017-05-08 |
JP2018529354A (ja) | 2018-10-11 |
CN108473992A (zh) | 2018-08-31 |
EP3366776A4 (en) | 2019-04-10 |
RU2018117175A3 (ko) | 2019-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101261147B1 (ko) | L-아미노산의 생산능이 향상된 미생물 및 이를 이용하여 l-아미노산을 생산하는 방법 | |
JP4541345B2 (ja) | L−リジン生産能の向上したコリネバクテリウム属微生物、およびそれを利用してl−リジンを生産する方法 | |
WO2009096689A2 (ko) | 개량된 프로모터 및 이를 이용한 l-라이신의 생산 방법 | |
EP3272860B1 (en) | Pyruvate dehydrogenase mutant, microorganism comprising mutant, and method for producing l-amino acid by using microorganism | |
WO2010093182A2 (ko) | L-아미노산 생산용 미생물 및 이를 이용하여 l-아미노산을 생산하는 방법 | |
WO2017069567A1 (ko) | L-쓰레오닌을 생산하는 재조합 미생물 및 이를 이용하여 l-쓰레오닌을 생산하는 방법 | |
WO2016171392A1 (ko) | 글루코네이트 리프레서 변이체, 이를 포함하는 l-라이신을 생산하는 미생물 및 이를 이용한 l-라이신 생산방법 | |
WO2015199406A1 (ko) | L-트립토판 생산능을 갖는 에스케리키아속 미생물 및 이를 이용한 l-트립토판의 제조 방법 | |
WO2014126384A1 (ko) | L-쓰레오닌 생산능을 가지는 재조합 에스케리키아 속 미생물 및 이를 이용한 l-쓰레오닌의 생산방법 | |
WO2015122569A1 (ko) | L-쓰레오닌 생산능을 가지는 재조합 에스케리키아 속 미생물 및 이를 이용한 l-쓰레오닌의 생산방법 | |
WO2022191357A1 (ko) | L-라이신 생산능이 향상된 코리네박테리움 글루타미쿰 변이주 및 이를 이용한 l-라이신의 생산 방법 | |
WO2022050527A1 (ko) | L-라이신 생산능이 향상된 코리네박테리움 글루타미쿰 변이주 및 이를 이용한 l-라이신의 생산 방법 | |
WO2015186958A1 (ko) | O-숙시닐호모세린 또는 숙신산의 생산능을 갖는 미생물 및 이를 이용한 숙신산 또는 o-숙시닐호모세린의 생산 방법 | |
WO2017065457A1 (ko) | L-쓰레오닌 생산능을 가지는 미생물 및 그를 이용하여 l-쓰레오닌을 생산하는 방법 | |
WO2022231054A1 (ko) | L-라이신 생산능이 향상된 코리네박테리움 글루타미쿰 변이주 및 이를 이용한 l-라이신의 생산 방법 | |
WO2023063547A1 (ko) | L-라이신 생산능이 향상된 코리네박테리움 글루타미쿰 변이주 및 이를 이용한 l-라이신의 생산 방법 | |
WO2023106543A1 (ko) | L-라이신 생산능이 향상된 코리네박테리움 글루타미쿰 변이주 및 이를 이용한 l-라이신의 생산 방법 | |
WO2015142021A1 (en) | Microorganisms having enhanced l-amino acids productivity and process for producing l-amino acids using the same | |
WO2022191358A1 (ko) | L-라이신 생산능이 향상된 코리네박테리움 글루타미쿰 변이주 및 이를 이용한 l-라이신의 생산 방법 | |
WO2022050524A1 (ko) | L-라이신 생산능이 향상된 코리네박테리움 글루타미쿰 변이주 및 이를 이용한 l-라이신의 생산 방법 | |
WO2022231049A1 (ko) | L-라이신 생산능이 향상된 코리네박테리움 글루타미쿰 변이주 및 이를 이용한 l-라이신의 생산 방법 | |
EP4083197A1 (en) | Corynebacterium glutamicum mutant strain having enhanced l-lysine productivity and method of producing l-lysine using the same | |
WO2018151347A1 (ko) | L-쓰레오닌 생산능을 가지는 미생물 및 그를 이용하여 l-쓰레오닌을 생산하는 방법 | |
WO2023136421A1 (ko) | L-히스티딘 생산능이 향상된 에스케리치아 속 변이주 및 이를 이용한 l-히스티딘의 생산 방법 | |
WO2017159976A1 (ko) | 퓨트레신을 생산하는 미생물 및 이를 이용한 퓨트레신 생산 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16857824 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018516546 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112018008045 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018117175 Country of ref document: RU Ref document number: 2016857824 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112018008045 Country of ref document: BR Kind code of ref document: A2 Effective date: 20180420 |